BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 18508462)

  • 1. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
    Flatt PR; Bailey CJ; Green BD
    Front Biosci; 2008 May; 13():3648-60. PubMed ID: 18508462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
    Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
    Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPP-4 inhibitors: what may be the clinical differentiators?
    Gerich J
    Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
    Ahrén B
    Curr Diab Rep; 2007 Oct; 7(5):340-7. PubMed ID: 18173966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N
    Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 inhibitors in clinical practice.
    Palalau AI; Tahrani AA; Piya MK; Barnett AH
    Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
    Wani JH; John-Kalarickal J; Fonseca VA
    Cardiol Clin; 2008 Nov; 26(4):639-48. PubMed ID: 18929237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Incretin related agents for treatment of diabetes mellitus].
    Miyagawa J; Miuchi M; Nanba M
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
    Ahrén B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch C
    Vasc Health Risk Manag; 2008; 4(4):753-68. PubMed ID: 19065993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
    Ahrén B
    Vasc Health Risk Manag; 2008; 4(2):383-94. PubMed ID: 18561513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
    Davidson JA; Parente EB; Gross JL
    Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.